RNA-Based Cancer Vaccines: Current Progress and Future Perspectives
RNA-based cancer vaccines are rapidly advancing, showing real clinical impact across multiple cancer types. Personalized mRNA vaccines for melanoma, combined with pembrolizumab, reduced recurrence or death risk by 44% compared to pembrolizumab alone. In pancreatic cancer, mRNA vaccines generated long-lasting T-cell responses in half of patients, persisting up to four years. At the University of […]
RNA-Based Cancer Vaccines: Current Progress and Future Perspectives Read More »